6,634 Shares in Spyre Therapeutics, Inc. $SYRE Acquired by AlphaCentric Advisors LLC

AlphaCentric Advisors LLC acquired a new stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE) during the first quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 6,634 shares of the company’s stock, valued at approximately $335,000.

Several other large investors have also recently added to or reduced their stakes in the company. Summit Securities Group LLC bought a new stake in Spyre Therapeutics in the 1st quarter valued at about $28,000. KBC Group NV bought a new position in Spyre Therapeutics during the 1st quarter worth $69,000. Russell Investments Group Ltd. raised its holdings in Spyre Therapeutics by 2,881.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 4,234 shares of the company’s stock valued at $71,000 after acquiring an additional 4,092 shares in the last quarter. Persistent Asset Partners Ltd bought a new stake in shares of Spyre Therapeutics during the 4th quarter valued at $74,000. Finally, Tower Research Capital LLC TRC lifted its position in shares of Spyre Therapeutics by 182.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,769 shares of the company’s stock valued at $86,000 after acquiring an additional 3,725 shares during the period. Institutional investors own 80.39% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on SYRE shares. Wedbush restated an “outperform” rating and issued a $100.00 price target on shares of Spyre Therapeutics in a research report on Tuesday, June 16th. Leerink Partners increased their price objective on shares of Spyre Therapeutics from $49.00 to $106.00 and gave the stock an “outperform” rating in a research note on Monday, April 13th. Mizuho raised their target price on shares of Spyre Therapeutics from $84.00 to $120.00 and gave the company an “outperform” rating in a report on Monday, July 13th. Stifel Nicolaus boosted their target price on shares of Spyre Therapeutics from $92.00 to $107.00 and gave the company a “buy” rating in a research report on Wednesday, May 6th. Finally, Deutsche Bank Aktiengesellschaft upped their price target on shares of Spyre Therapeutics from $115.00 to $135.00 and gave the stock a “buy” rating in a report on Tuesday, June 23rd. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $101.42.

Insider Transactions at Spyre Therapeutics

In other Spyre Therapeutics news, Director Michael Thomas Henderson sold 80,000 shares of the company’s stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $74.40, for a total value of $5,952,000.00. Following the completion of the transaction, the director owned 88,606 shares of the company’s stock, valued at $6,592,286.40. This represents a 47.45% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Cameron Turtle sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $70.43, for a total transaction of $1,056,450.00. Following the completion of the transaction, the chief executive officer owned 597,540 shares of the company’s stock, valued at approximately $42,084,742.20. This trade represents a 2.45% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 282,500 shares of company stock worth $21,741,101 in the last 90 days. 15.69% of the stock is currently owned by company insiders.

Spyre Therapeutics Stock Performance

Shares of Spyre Therapeutics stock opened at $100.23 on Monday. The firm has a market capitalization of $8.81 billion, a PE ratio of -48.19 and a beta of 3.02. The firm’s 50 day moving average is $82.96 and its 200 day moving average is $58.37. Spyre Therapeutics, Inc. has a 1 year low of $14.51 and a 1 year high of $105.09.

Spyre Therapeutics (NASDAQ:SYRE) last issued its earnings results on Tuesday, May 5th. The company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.08). As a group, research analysts anticipate that Spyre Therapeutics, Inc. will post -2.86 earnings per share for the current year.

Spyre Therapeutics Profile

Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications.

Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts.